ClinicalTrials.gg
Not yet recruitingNCT07687225POSITIVE-BoneUpdated Jul 7, 2026

Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases

An interventional study of Primary Tumor Resection and Standard systemic therapy in Breast Cancer, Stage IV Breast Cancer and Bone Metastases, sponsored by West China Hospital. Not yet recruiting. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by West China Hospital · Not applicable, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Breast Neoplasms by West China Hospital — 6 open to participants now, 6 under way, 1 of them phase 3. Breast Neoplasms · West China Hospital.

Started
2026
with 4 others
No phase
2 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Breast Neoplasms by West China Hospital, this one is one of 5 that started in 2026, is one of 2 with no phase, and was the 11th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 11 studies in Breast Neoplasms by West China Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Breast Neoplasms by West China Hospital, or all of them as a file.
02

Study summary

This is a national multicenter, prospective, randomized controlled trial. The study aims to compare the 5-year overall survival (OS) between patients receiving primary tumor surgery followed by systemic therapy (surgery group) and those receiving systemic therapy alone (non-surgery group) in patients with de novo Stage IV breast cancer who have solitary bone metastases. Secondary objectives include comparing progression-free survival (PFS), breast cancer-specific survival (BCSS), local control rates, patient-reported outcomes (BREAST-Q, QLQ-C30), safety (surgical complications and systemic therapy toxicities), and cost-effectiveness.

Read the detailed description

The value of primary tumor resection in de novo stage IV breast cancer (BC) remains debated. While early retrospective studies suggested a potential survival benefit, recent large-scale randomized controlled trials (e.g., JCOG1017, E2108) have shown no OS benefit for the overall stage IV BC population. However, exploratory subgroup analyses consistently point towards a potential benefit for patients with hormone receptor-positive (HR+) disease and low metastatic burden, such as solitary bone metastases.

Given the unique biological behavior of HR+ BC and the effectiveness of modern systemic therapies (e.g., endocrine therapy + CDK4/6 inhibitors), it is hypothesized that primary tumor surgery may provide an additional "consolidation" benefit in this specific subgroup by improving local control and potentially prolonging survival. To address this, our team has designed this national multicenter, prospective, randomized controlled trial.

This study will enroll patients with de novo stage IV BC confirmed to have only bone metastases. All participants will receive standard systemic therapy based on their molecular subtype. Participants will be randomized 1:1 to either undergo primary tumor surgery (mastectomy or breast-conserving surgery with or without immediate reconstruction) within 4 weeks of randomization, followed by continued systemic therapy, or to receive systemic therapy alone. Palliative radiotherapy for bone metastases is permitted in both arms. The primary endpoint is 5-year overall survival. Secondary endpoints include PFS, BCSS, local control rate, quality of life (BREAST-Q, QLQ-C30), surgical complication rates, and cost analysis. This study will provide high-level evidence to guide personalized treatment decisions for this specific patient subgroup in China.

03

Conditions studied

  • Breast Cancer
  • Stage IV Breast Cancer
  • Bone Metastases

Browse trials for

Keywords

  • Breast Cancer
  • Stage IV
  • Bone Metastasis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to 70 years (inclusive);
  • Histopathologically confirmed (by core needle ) invasive breast cancer;
  • Diagnosed with de novo Stage IV breast cancer with confirmed to be limited to bone;
  • Patients may be enrolled either at initial diagnosis or after receiving systemic therapy;
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Disease progression (per 1.1 criteria) in the primary tumor, regional lymph nodes, or bone after systemic therapy;
  • Presence of other primary ;
  • Severe comorbidities that would preclude surgery or safe administration of systemic therapy (e.g., severe cardiopulmonary disease, uncontrolled diabetes, long-term smoking history with poor pulmonary function, immunodeficiency);
  • Current participation in another clinical trial that would interfere with the outcomes of this study;
  • Refusal to provide .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    Surgery Group

    Patients undergo primary tumor surgery (total mastectomy or breast-conserving surgery with sentinel lymph node biopsy or axillary lymph node dissection, with or without immediate breast reconstruction) within 4 weeks after randomization, followed by continued standard systemic therapy.

    Procedure: Primary Tumor Resection

  • Active comparator
    Non-Surgery Group

    Patients receive standard systemic therapy alone based on their molecular subtype (e.g., HR+/HER2-: endocrine therapy ± CDK4/6 inhibitor; HER2+: anti-HER2 therapy + chemotherapy; Triple-negative: chemotherapy ± immunotherapy). Palliative local therapy (e.g., radiotherapy) for bone metastases or for managing severe local complications from the primary tumor (e.g., uncontrolled ulceration, bleeding) is permitted but not elective curative-intent primary tumor surgery.

    Other: Standard systemic therapy

Interventions

  • ProcedurePrimary Tumor Resection

    Surgical removal of the primary breast tumor. The procedure type (mastectomy or breast-conserving surgery) is determined by tumor size, location, and patient preference, and is performed by experienced breast surgeons following national guidelines. Axillary staging (sentinel node biopsy or dissection) is performed concurrently. Immediate breast reconstruction (prosthesis or autologous tissue) may be performed when indicated.

  • OtherStandard systemic therapy

    Systemic treatment administered according to the patient's molecular subtype (HR+, HER2+, or Triple-negative) based on Chinese and international clinical guidelines. Regimens include, but are not limited to, endocrine therapy (e.g., letrozole, exemestane) with or without CDK4/6 inhibitors (e.g., palbociclib) for HR+/HER2- disease; anti-HER2 targeted therapy (e.g., trastuzumab, pertuzumab) combined with chemotherapy for HER2+ disease; and chemotherapy (e.g., taxanes, anthracyclines) with or without immunotherapy (e.g., pembrolizumab) for triple-negative disease. All patients with bone metastases routinely receive bone-modifying agents (zoledronic acid or denosumab).

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., PertuzumabStudies of PertuzumabPertuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., PalbociclibStudies of PalbociclibPalbociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time from randomization to death from any cause.

    Time frame: 5 years post-randomization

Secondary outcomes

  1. Overall Survival (OS)

    Time from randomization to death from any cause.

    Time frame: 3 and 10 years post-randomization

  2. Progression-Free Survival (PFS)

    Time from randomization to first documented disease progression (local progression, regional recurrence, or new/ progressive distant metastases) or death from any cause.

    Time frame: Up to 10 years post-randomization

  3. Breast Cancer-Specific Survival (BCSS)

    Time from randomization to death due to breast cancer.

    Time frame: Up to 10 years post-randomization

  4. Patient-Reported Outcomes (PROs)

    Quality of life measured by the EORTC QLQ-C30 (global health status/QoL).

    Time frame: Baseline, 6 months, 5 years, and 10 years post-randomization.

  5. Patient-Reported Outcomes (PROs)

    Quality of satisfaction measured by the BREAST-Q (psychosocial well-being, sexual well-being, and chest physical well-being) questionnaires.

    Time frame: Baseline, 6 months, 5 years, and 10 years post-randomization.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data via the request portal. All IPD requests should be emailed to Dr. Zhenggui Du, the general project leader, and will be evaluated by Dr. Du and the head of the collaborating organization to decide whether to approve.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After publication of relevant research outputs, such as academic papers and books.

Access criteria: When a request has been approved, the investigator will provide access to the de-identified individual patient-level data in the data management platform (Electronic Data Capture, EDC). A signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing the requested information. Additionally, all users will need to accept the terms and conditions of the data management platform to gain access.

Data sharing details ↗ · dct.meddb.cn

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2031, 60 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 60 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jul 7, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Sep 1, 2031
CompletionEst.
Dec 31, 2036
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07687225
Collaborators
The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, The Nineth Hospital of Shenzhen, Longgang Center Hospital, Baotou Cancer Hospital, Hebei General Hospital, General Hospital of Ningxia Medical University, The First Hospital of Jilin University, Tangshan People's Hospital, Guangdong Women and Children Hospital, Nanchang People's Hospital, Cancer Hospital of Guangxi Medical University, Xinjiang Medical University Cancer Hospital, Anyang Tumor Hospital, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Shanxi Bethune Hospital, Hebei Medical University Fourth Hospital, The Affiliated Hospital of Qingdao University, Suzhou Municipal Hospital, Zhejiang Provincial People's Hospital, Hunan Cancer Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Shanxi Province Cancer Hospital, LanZhou University, Lanzhou University Second Hospital
Responsible party
Du Zhenggui (Dr., West China Hospital) — Principal investigator
First posted
Jul 7, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 1, 2031 (estimated)
Completion
Dec 31, 2036 (estimated)
Last update
Jul 7, 2026

Study contacts

Zhenggui Du
Contact
docduzg@163.com
+86 13880768222
Liuying Li
Contact
lliuying99@163.com
+86 13678020999

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion